A novel bispecific T-cell engager(BiTE)has been developed as an efficient immunotherapeutic molecule specifically bringing the T-cell and the tumor target together for enhanced immunotherapy.The general BiTE construct consists of two single-chain variable antibody fragments(scFvs)targeting a tumor-...
LAVA-1207Bispecific T cell engager antibodyGCP2, PSMA, TCR• Hormone-resistant prostate cancer • Solid tumorPhase 2 Recommended Services Anti-idiotype Antibody Production Services Nanobody Development and Production Platform Nanobodies are very promising next-generation therapeutic antibodies that have ...
The use of bispecific antibodies for redirecting the cytotoxic activity of T cells in a non-major histocompatibility complex restricted fashion has expanded in recent years, with a particular thrust by promising clinical results obtained with blinatumomab, a CD19/CD3 bispecific T-cell engager (TCE) ...
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity human albumin sequences engineered with either null (NB), wild type (WT) or high binding (HB) FcRn affinity combined with a bispecific T-cell engager... OA Mandrup,CO Sui,S ...
Methods: Given the therapeutic potential of nanobodies (Nbs), we first screened Nb targeting fibroblast activation protein (FAP) and successfully generated a Nb-based bispecific T cell engager (Nb-BiTE) targeting FAP. Then, we developed a Nb-TriTE by fusing an anti-PD-1 Nb to the Nb-BiTE...